Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA recognition of standards

This article was originally published in The Gray Sheet

Executive Summary

Draft guidance on use of the International Electrotechnical Commission's 60601 safety standards for devices will not be finalized, FDA says in an Oct. 16 Federal Register notice. Instead, the agency formally recognizes the 60601 standards by listing them in the notice, along with 240 other standards posted on FDA's website in August. "There appears to be little, if any benefit to finalizing guidance on FDA's use of IEC 60601 standards in a separate document," the notice says

You may also be interested in...



IEC Electromedical Safety Standard Third Edition Expected In August 2005

Manufacturers planning declarations of conformity to the third edition of the International Engineering Consortium's electromedical equipment standard should come into compliance with international risk management standard ISO 14971, panelists at a recent AAMI/FDA meeting suggested

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel